Close Menu

CHICAGO (GenomeWeb) – A team led by the Institute of Cancer Research in the UK has used exome sequencing in an effort to tease out prostate cancer molecular features that are associated with a response to the checkpoint blockade immunotherapy drug pembrolizumab (Merck's Keytruda).

At the American Society of Clinical Oncology meeting here this week, Johann de Bono, director of the ICR's drug development unit, shared data from the Keynote-199 study, a Phase II trial comparing pembrolizumab response in 258 metastatic prostate cancer cases with or without tumor expression of PD-L1.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
21

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.